Isomorphic Labs Series B: Isomorphic Labs raised $2.1 Billion funding to scale its AI drug design engine
HQ: UK
Founded: 2021
Series B
Sector: AI, BioTech, Pharmaceutical
Investment Raised: USD 2.1b €
Valuation Remains Undisclosed
Investors: The round was led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund
Adcendo Series C: $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
HQ: DK
Founded: 2017
Series C
Sector: BioTech, Pharmaceutical
Investment Raised: USD 75m €
Valuation Remains Undisclosed
Investors: The round was led Jeito Capital, with participation from additional new investors Vida Ventures, BPI France, and EIFO (Export and Investment Fund of Denmark), as well as all existing investors, including TCGX, RA Capital Management, TPG, Orbimed, Venrock, Surveyor, Logos Capital, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital.
Investors: SKS PE Daishin Private Equity (https://www.daishin.com/) SKS PE InterVest (http://intervest.co.kr/en) KDB Bank (http://www.kdbbank.eu/) Asset One Kakao Ventures (http://www.medium.com/kakaoventures) LB Investment (http://lbinvestment.com/) Atinum Investment (http://www.atinuminvest.co.kr/) DSC Investment and Wonik Investment Partners.
